<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00536731</url>
  </required_header>
  <id_info>
    <org_study_id>D5897C00003</org_study_id>
    <nct_id>NCT00536731</nct_id>
  </id_info>
  <brief_title>Symbicort Rapihaler Therapeutic Equivalence Study</brief_title>
  <acronym>ESTHER</acronym>
  <official_title>A 6-week, Phase III, Double-blind, Randomized, Multi-centre, Parallel-group Study Evaluating the Efficacy and Safety of 2 Actuations Symbicort®pMDI® 40/2.25 μg Twice Daily Compared With 1 Inhalation Symbicort Turbuhaler® 80/4.5 μg Twice Daily and 1 Inhalation Pulmicort®Turbuhaler® 100 μg Twice Daily</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>AstraZeneca</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>AstraZeneca</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The purpose of the this study is to evaluate the efficacy and safety of 2 actuations
      Symbicort®pMDI® 40/2.25 μg twice daily compared with1 inhalation Symbicort Turbuhaler® 80/4.5
      μg twice daily and 1 inhalation Pulmicort®Turbuhaler® 100 μg twice daily for 6 weeks.
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date>September 2007</start_date>
  <completion_date type="Actual">April 2008</completion_date>
  <primary_completion_date type="Actual">April 2008</primary_completion_date>
  <phase>Phase 3</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Morning Peak Expiratory Flow (PEF)</measure>
    <time_frame>Baseline to 6 weeks</time_frame>
    <description>Change in the Morning PEF from baseline (calculated as a mean using all available data for the 10 last days of run-in period) to week 6 (calculated as a mean using all available data after randomisation). No imputation of missing data was performed</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Evening Peak Expiratory Flow (PEF)</measure>
    <time_frame>Baseline to 6 weeks</time_frame>
    <description>Change in the Evening PEF from baseline (calculated as a mean using all available data for the 10 last days of run-in period) to week 6 (calculated as a mean using all available data after randomisation). No imputation of missing data was performed</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Asthma Symptom Score, Night</measure>
    <time_frame>Baseline to 6 weeks</time_frame>
    <description>Change in the Asthma Symptom Score (Night) from baseline (calculated as a mean using all available data for the 10 last days of run-in period) to week 6 (calculated as a mean using all available data after randomization, with run-in values as covariate). No imputation of missing data was performed. Daily scale:0 = No symptoms; 1 = Mild symptoms; 2 = Moderate symptoms; 3 = Severe symptoms.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Asthma Symptom Score, Day</measure>
    <time_frame>Baseline to 6 weeks</time_frame>
    <description>Change in the Asthma Symptom Score (Day) from baseline (calculated as a mean using all available data for the 10 last days of run-in period) to week 6 (calculated as a mean using all available data after randomization, with run-in values as covariate). No imputation of missing data was performed. Daily scale:0 = No symptoms; 1 = Mild symptoms; 2 = Moderate symptoms; 3 = Severe symptoms.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Asthma Symptom Score, Total</measure>
    <time_frame>Baseline to 6 weeks</time_frame>
    <description>Change in the Asthma Symptom Score (Total) from baseline (calculated as a mean using all available data for the 10 last days of run-in period) to week 6 (calculated as a mean using all available data after randomization, with run-in values as covariate). No imputation of missing data was performed. Daily scale:0 = No symptoms; 1 = Mild symptoms; 2 = Moderate symptoms; 3 = Severe symptoms.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Percentage of Nights With Awakenings Due to Asthma</measure>
    <time_frame>Baseline and 6 weeks</time_frame>
    <description>Change in the Percentage of Nights With Awakenings Due to Asthma from baseline (calculated as a mean using all available data for the 10 last days of run-in period) to week 6 (calculated as a mean using all available data after randomization, with run-in values as covariate). No imputation of missing data was performed. The participants answered &quot;Yes&quot; or &quot;No&quot; whether she/he woke up during the night due to asthma.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Use of Rescue Medication, Night</measure>
    <time_frame>Baseline to 6 weeks</time_frame>
    <description>Change in the Use of Rescue Medication (Night) from baseline (calculated as a mean using all available data for the 10 last days of run-in period) to week 6 (calculated as a mean using all available data after randomization, with run-in values as covariate). No imputation of missing data was performed</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Use of Rescue Medication, Day</measure>
    <time_frame>Baseline to 6 weeks</time_frame>
    <description>Change in the Use of Rescue Medication (Day) from baseline (calculated as a mean using all available data for the 10 last days of run-in period) to week 6 (calculated as a mean using all available data after randomization, with run-in values as covariate). No imputation of missing data was performed</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Use of Rescue Medication, Total</measure>
    <time_frame>Baseline to 6 weeks</time_frame>
    <description>Change in the Use of Rescue Medication (Total) from baseline (calculated as a mean using all available data for the 10 last days of run-in period) to week 6 (calculated as a mean using all available data after randomization, with run-in values as covariate). No imputation of missing data was performed</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Percentage of Symptom-free Days</measure>
    <time_frame>Baseline to 6 weeks</time_frame>
    <description>Change in the Percentage of Symptom-free Days from baseline (calculated as a mean using all available data for the 10 last days of run-in period) to week 6 (calculated as a mean using all available data after randomization, with run-in values as covariate). No imputation of missing data was performed. Symptom-free Day: no symptoms (asthma symptom score=0) night and day, and no awakenings due to asthma.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Percentage of Asthma Control Days</measure>
    <time_frame>Baseline to 6 weeks</time_frame>
    <description>Change in the Percentage of Symptom Control Days from baseline (calculated as a mean using all available data for the 10 last days of run-in period) to week 6 (calculated as a mean using all available data after randomization, with run-in values as covariate). No imputation of missing data was performed. Asthma Control Day: no symptoms (asthma symptom score=0) night and day, no awakenings due to asthma, no rescue medication.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Percentage of Rescue Free Days</measure>
    <time_frame>Baseline to 6 weeks</time_frame>
    <description>Change in the Percentage of Rescue Free Days from baseline (calculated as a mean using all available data for the 10 last days of run-in period) to week 6 (calculated as a mean using all available data after randomization, with run-in values as covariate). No imputation of missing data was performed. Rescue-free Day defined as day and night with no use of rescue medication.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Forced Expiratory Volume in 1 Second (FEV1)</measure>
    <time_frame>Baseline to 6 weeks</time_frame>
    <description>Change in the FEV1from baseline to week 6 (calculated as a mean using all available data after randomization)</description>
  </secondary_outcome>
  <number_of_arms>3</number_of_arms>
  <enrollment type="Actual">742</enrollment>
  <condition>Bronchial Asthma</condition>
  <arm_group>
    <arm_group_label>Symbicort pMDI</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Symbicort®pMDI® 40/2.25 μg 2 Actuations Twice Daily</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Symbicort Turbuhaler</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Symbicort Turbuhaler® 80/4.5 μg 1 Inhalation Twice Daily</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Pulmicort Turbuhaler</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Pulmicort®Turbuhaler® 100 μg 1 Inhalation Twice Daily</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Symbicort Turbuhaler</intervention_name>
    <description>Symbicort Turbuhaler® 80/4.5 μg 1 Inhalation Twice Daily</description>
    <arm_group_label>Symbicort Turbuhaler</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Symbicort pMDI</intervention_name>
    <description>Symbicort®pMDI® 40/2.25 μg 2 Actuations Twice Daily</description>
    <arm_group_label>Symbicort pMDI</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Pulmicort Turbuhaler</intervention_name>
    <description>Pulmicort®Turbuhaler® 100 μg 1 Inhalation Twice Daily</description>
    <arm_group_label>Pulmicort Turbuhaler</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Asthma clinically diagnosed since at least 6 months.

          -  Lung function values measured ≥ 50% and ≤ 90% of predicted normal.

          -  Patients with reversible airway obstruction Daily use of inhaled steroids (any brand)
             for &gt;3 months.

        Exclusion Criteria:

          -  Use of oral, rectal or parenteral steroids within 30 days prior to start of study.

          -  Respiratory infection affecting the asthma, as judged by the investigator, within 30
             days prior to start of randomised treatment.

          -  Any significant disease or disorder which, in the opinion of the investigator, may
             either put the patient at risk because of participation in the study, or may influence
             the results of the study or the patient's ability to participate in the study.
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>12 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Tomas Andersson</last_name>
    <role>Study Director</role>
    <affiliation>AstraZeneca</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Akos Somoskovi</last_name>
    <role>Principal Investigator</role>
    <affiliation>AstraZeneca</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Pleven</city>
        <country>Bulgaria</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Plovdiv</city>
        <country>Bulgaria</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Rousse</city>
        <country>Bulgaria</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Sofia</city>
        <country>Bulgaria</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Varna</city>
        <country>Bulgaria</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Benesov U Prahy</city>
        <country>Czech Republic</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Hradec Kralove</city>
        <country>Czech Republic</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Jihlava</city>
        <country>Czech Republic</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Kladno</city>
        <country>Czech Republic</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Kolin</city>
        <country>Czech Republic</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Kutna Hora</city>
        <country>Czech Republic</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Litomerice</city>
        <country>Czech Republic</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Neratovice</city>
        <country>Czech Republic</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Pardubice</city>
        <country>Czech Republic</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Praha 4</city>
        <country>Czech Republic</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Praha 5</city>
        <country>Czech Republic</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Praha 8</city>
        <country>Czech Republic</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Rokycany</city>
        <country>Czech Republic</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Strakonice</city>
        <country>Czech Republic</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Balassagyarmat</city>
        <country>Hungary</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Budapest</city>
        <country>Hungary</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Cegléd</city>
        <country>Hungary</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Debrecen</city>
        <country>Hungary</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Deszk</city>
        <country>Hungary</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Gyor</city>
        <country>Hungary</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Gyula</city>
        <country>Hungary</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Kaposvar</city>
        <country>Hungary</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Nyíregyháza</city>
        <country>Hungary</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Szarvas</city>
        <country>Hungary</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Szeged</city>
        <country>Hungary</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Százhalombatta</city>
        <country>Hungary</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Törökbálint</city>
        <country>Hungary</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Bialystok</city>
        <country>Poland</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Bielsko-biala</city>
        <country>Poland</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Bydgoszcz</city>
        <country>Poland</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Chodziez</city>
        <country>Poland</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Chrzanow</city>
        <country>Poland</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Karpacz</city>
        <country>Poland</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Krakow</city>
        <country>Poland</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Lodz</city>
        <country>Poland</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Lomza</city>
        <country>Poland</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Lublin</city>
        <country>Poland</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Ostrow Wielkopolski</city>
        <country>Poland</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Poznan</city>
        <country>Poland</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Skierniewice</city>
        <country>Poland</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Szczecin</city>
        <country>Poland</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Tarnow</city>
        <country>Poland</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Turek</city>
        <country>Poland</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Wodzislaw Slaski</city>
        <country>Poland</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Wroclaw</city>
        <country>Poland</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Bulgaria</country>
    <country>Czech Republic</country>
    <country>Hungary</country>
    <country>Poland</country>
  </location_countries>
  <verification_date>August 2012</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>September 27, 2007</study_first_submitted>
  <study_first_submitted_qc>September 27, 2007</study_first_submitted_qc>
  <study_first_posted type="Estimate">September 28, 2007</study_first_posted>
  <results_first_submitted>April 1, 2009</results_first_submitted>
  <results_first_submitted_qc>August 14, 2012</results_first_submitted_qc>
  <results_first_posted type="Estimate">August 15, 2012</results_first_posted>
  <last_update_submitted>August 14, 2012</last_update_submitted>
  <last_update_submitted_qc>August 14, 2012</last_update_submitted_qc>
  <last_update_posted type="Estimate">August 15, 2012</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Asthma</keyword>
  <keyword>Symbicort</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Asthma</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Budesonide, Formoterol Fumarate Drug Combination</mesh_term>
    <mesh_term>Budesonide</mesh_term>
  </intervention_browse>

  <clinical_results>

    <participant_flow>
      <recruitment_details>898 subjects enrolled; 156 not randomised: 94 incorrect enrolment, 9 adverse events, 18 voluntary discontinuations, 1 lost to follow-up, 1use of not allowed medication, 1 non-compliant</recruitment_details>
      <group_list>
        <group group_id="P1">
          <title>Symbicort pMDI</title>
          <description>Symbicort®pMDI® 40/2.25 μg 2 Actuations Twice Daily</description>
        </group>
        <group group_id="P2">
          <title>Symbicort Turbuhaler</title>
          <description>Symbicort Turbuhaler® 80/4.5 μg 1 Inhalation Twice Daily</description>
        </group>
        <group group_id="P3">
          <title>Pulmicort Turbuhaler</title>
          <description>Pulmicort®Turbuhaler® 100 μg 1 Inhalation Twice Daily</description>
        </group>
      </group_list>
      <period_list>
        <period>
          <title>Overall Study</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="253"/>
                <participants group_id="P2" count="246"/>
                <participants group_id="P3" count="243"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="249"/>
                <participants group_id="P2" count="241"/>
                <participants group_id="P3" count="238"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="4"/>
                <participants group_id="P2" count="5"/>
                <participants group_id="P3" count="5"/>
              </participants_list>
            </milestone>
          </milestone_list>
          <drop_withdraw_reason_list>
            <drop_withdraw_reason>
              <title>Adverse Event</title>
              <participants_list>
                <participants group_id="P1" count="3"/>
                <participants group_id="P2" count="2"/>
                <participants group_id="P3" count="3"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Withdrawal by Subject</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="2"/>
                <participants group_id="P3" count="0"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Intake of prohibited conc. medication</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="0"/>
                <participants group_id="P3" count="1"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Safety reasons</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="0"/>
                <participants group_id="P3" count="1"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Other</title>
              <participants_list>
                <participants group_id="P1" count="1"/>
                <participants group_id="P2" count="1"/>
                <participants group_id="P3" count="0"/>
              </participants_list>
            </drop_withdraw_reason>
          </drop_withdraw_reason_list>
        </period>
      </period_list>
    </participant_flow>

    <baseline>
      <group_list>
        <group group_id="B1">
          <title>Symbicort pMDI</title>
          <description>Symbicort®pMDI® 40/2.25 μg 2 Actuations Twice Daily</description>
        </group>
        <group group_id="B2">
          <title>Symbicort Turbuhaler</title>
          <description>Symbicort Turbuhaler® 80/4.5 μg 1 Inhalation Twice Daily</description>
        </group>
        <group group_id="B3">
          <title>Pulmicort Turbuhaler</title>
          <description>Pulmicort®Turbuhaler® 100 μg 1 Inhalation Twice Daily</description>
        </group>
        <group group_id="B4">
          <title>Total</title>
          <description>Total of all reporting groups</description>
        </group>
      </group_list>
      <analyzed_list>
        <analyzed>
          <units>Participants</units>
          <scope>Overall</scope>
          <count_list>
            <count group_id="B1" value="253"/>
            <count group_id="B2" value="246"/>
            <count group_id="B3" value="243"/>
            <count group_id="B4" value="742"/>
          </count_list>
        </analyzed>
      </analyzed_list>
      <measure_list>
        <measure>
          <title>Age</title>
          <units>years</units>
          <param>Mean</param>
          <dispersion>Full Range</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="41" lower_limit="12" upper_limit="75"/>
                    <measurement group_id="B2" value="42" lower_limit="12" upper_limit="76"/>
                    <measurement group_id="B3" value="39" lower_limit="12" upper_limit="78"/>
                    <measurement group_id="B4" value="41" lower_limit="12" upper_limit="78"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Gender</title>
          <units>Participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>Female</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="152"/>
                    <measurement group_id="B2" value="142"/>
                    <measurement group_id="B3" value="131"/>
                    <measurement group_id="B4" value="425"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Male</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="101"/>
                    <measurement group_id="B2" value="104"/>
                    <measurement group_id="B3" value="112"/>
                    <measurement group_id="B4" value="317"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </measure_list>
    </baseline>

    <outcome_list>
      <outcome>
        <type>Primary</type>
        <title>Morning Peak Expiratory Flow (PEF)</title>
        <description>Change in the Morning PEF from baseline (calculated as a mean using all available data for the 10 last days of run-in period) to week 6 (calculated as a mean using all available data after randomisation). No imputation of missing data was performed</description>
        <time_frame>Baseline to 6 weeks</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Symbicort pMDI</title>
            <description>Symbicort®pMDI® 40/2.25 μg 2 Actuations Twice Daily</description>
          </group>
          <group group_id="O2">
            <title>Symbicort Turbuhaler</title>
            <description>Symbicort Turbuhaler® 80/4.5 μg 1 Inhalation Twice Daily</description>
          </group>
          <group group_id="O3">
            <title>Pulmicort Turbuhaler</title>
            <description>Pulmicort®Turbuhaler® 100 μg 1 Inhalation Twice Daily</description>
          </group>
        </group_list>
        <measure>
          <title>Morning Peak Expiratory Flow (PEF)</title>
          <description>Change in the Morning PEF from baseline (calculated as a mean using all available data for the 10 last days of run-in period) to week 6 (calculated as a mean using all available data after randomisation). No imputation of missing data was performed</description>
          <units>Liters/min</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="253"/>
                <count group_id="O2" value="245"/>
                <count group_id="O3" value="243"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="12.88" spread="24.6"/>
                    <measurement group_id="O2" value="13.78" spread="29.7"/>
                    <measurement group_id="O3" value="4.59" spread="27.9"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Evening Peak Expiratory Flow (PEF)</title>
        <description>Change in the Evening PEF from baseline (calculated as a mean using all available data for the 10 last days of run-in period) to week 6 (calculated as a mean using all available data after randomisation). No imputation of missing data was performed</description>
        <time_frame>Baseline to 6 weeks</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Symbicort pMDI</title>
            <description>Symbicort®pMDI® 40/2.25 μg 2 Actuations Twice Daily</description>
          </group>
          <group group_id="O2">
            <title>Symbicort Turbuhaler</title>
            <description>Symbicort Turbuhaler® 80/4.5 μg 1 Inhalation Twice Daily</description>
          </group>
          <group group_id="O3">
            <title>Pulmicort Turbuhaler</title>
            <description>Pulmicort®Turbuhaler® 100 μg 1 Inhalation Twice Daily</description>
          </group>
        </group_list>
        <measure>
          <title>Evening Peak Expiratory Flow (PEF)</title>
          <description>Change in the Evening PEF from baseline (calculated as a mean using all available data for the 10 last days of run-in period) to week 6 (calculated as a mean using all available data after randomisation). No imputation of missing data was performed</description>
          <units>Liters/min</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="253"/>
                <count group_id="O2" value="245"/>
                <count group_id="O3" value="243"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="12.34" spread="24.3"/>
                    <measurement group_id="O2" value="10.80" spread="29.1"/>
                    <measurement group_id="O3" value="1.43" spread="25.7"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Asthma Symptom Score, Night</title>
        <description>Change in the Asthma Symptom Score (Night) from baseline (calculated as a mean using all available data for the 10 last days of run-in period) to week 6 (calculated as a mean using all available data after randomization, with run-in values as covariate). No imputation of missing data was performed. Daily scale:0 = No symptoms; 1 = Mild symptoms; 2 = Moderate symptoms; 3 = Severe symptoms.</description>
        <time_frame>Baseline to 6 weeks</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Symbicort pMDI</title>
            <description>Symbicort®pMDI® 40/2.25 μg 2 Actuations Twice Daily</description>
          </group>
          <group group_id="O2">
            <title>Symbicort Turbuhaler</title>
            <description>Symbicort Turbuhaler® 80/4.5 μg 1 Inhalation Twice Daily</description>
          </group>
          <group group_id="O3">
            <title>Pulmicort Turbuhaler</title>
            <description>Pulmicort®Turbuhaler® 100 μg 1 Inhalation Twice Daily</description>
          </group>
        </group_list>
        <measure>
          <title>Asthma Symptom Score, Night</title>
          <description>Change in the Asthma Symptom Score (Night) from baseline (calculated as a mean using all available data for the 10 last days of run-in period) to week 6 (calculated as a mean using all available data after randomization, with run-in values as covariate). No imputation of missing data was performed. Daily scale:0 = No symptoms; 1 = Mild symptoms; 2 = Moderate symptoms; 3 = Severe symptoms.</description>
          <units>Units on a scale</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="253"/>
                <count group_id="O2" value="245"/>
                <count group_id="O3" value="243"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-0.24" spread="0.41"/>
                    <measurement group_id="O2" value="-0.27" spread="0.41"/>
                    <measurement group_id="O3" value="-0.15" spread="0.39"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Asthma Symptom Score, Day</title>
        <description>Change in the Asthma Symptom Score (Day) from baseline (calculated as a mean using all available data for the 10 last days of run-in period) to week 6 (calculated as a mean using all available data after randomization, with run-in values as covariate). No imputation of missing data was performed. Daily scale:0 = No symptoms; 1 = Mild symptoms; 2 = Moderate symptoms; 3 = Severe symptoms.</description>
        <time_frame>Baseline to 6 weeks</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Symbicort pMDI</title>
            <description>Symbicort®pMDI® 40/2.25 μg 2 Actuations Twice Daily</description>
          </group>
          <group group_id="O2">
            <title>Symbicort Turbuhaler</title>
            <description>Symbicort Turbuhaler® 80/4.5 μg 1 Inhalation Twice Daily</description>
          </group>
          <group group_id="O3">
            <title>Pulmicort Turbuhaler</title>
            <description>Pulmicort®Turbuhaler® 100 μg 1 Inhalation Twice Daily</description>
          </group>
        </group_list>
        <measure>
          <title>Asthma Symptom Score, Day</title>
          <description>Change in the Asthma Symptom Score (Day) from baseline (calculated as a mean using all available data for the 10 last days of run-in period) to week 6 (calculated as a mean using all available data after randomization, with run-in values as covariate). No imputation of missing data was performed. Daily scale:0 = No symptoms; 1 = Mild symptoms; 2 = Moderate symptoms; 3 = Severe symptoms.</description>
          <units>Units on a scale</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="253"/>
                <count group_id="O2" value="245"/>
                <count group_id="O3" value="243"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-0.21" spread="0.38"/>
                    <measurement group_id="O2" value="-0.24" spread="0.40"/>
                    <measurement group_id="O3" value="-0.15" spread="0.40"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Asthma Symptom Score, Total</title>
        <description>Change in the Asthma Symptom Score (Total) from baseline (calculated as a mean using all available data for the 10 last days of run-in period) to week 6 (calculated as a mean using all available data after randomization, with run-in values as covariate). No imputation of missing data was performed. Daily scale:0 = No symptoms; 1 = Mild symptoms; 2 = Moderate symptoms; 3 = Severe symptoms.</description>
        <time_frame>Baseline to 6 weeks</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Symbicort pMDI</title>
            <description>Symbicort®pMDI® 40/2.25 μg 2 Actuations Twice Daily</description>
          </group>
          <group group_id="O2">
            <title>Symbicort Turbuhaler</title>
            <description>Symbicort Turbuhaler® 80/4.5 μg 1 Inhalation Twice Daily</description>
          </group>
          <group group_id="O3">
            <title>Pulmicort Turbuhaler</title>
            <description>Pulmicort®Turbuhaler® 100 μg 1 Inhalation Twice Daily</description>
          </group>
        </group_list>
        <measure>
          <title>Asthma Symptom Score, Total</title>
          <description>Change in the Asthma Symptom Score (Total) from baseline (calculated as a mean using all available data for the 10 last days of run-in period) to week 6 (calculated as a mean using all available data after randomization, with run-in values as covariate). No imputation of missing data was performed. Daily scale:0 = No symptoms; 1 = Mild symptoms; 2 = Moderate symptoms; 3 = Severe symptoms.</description>
          <units>Units on a scale</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="253"/>
                <count group_id="O2" value="245"/>
                <count group_id="O3" value="243"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-0.45" spread="0.73"/>
                    <measurement group_id="O2" value="-0.51" spread="0.75"/>
                    <measurement group_id="O3" value="-0.30" spread="0.73"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Percentage of Nights With Awakenings Due to Asthma</title>
        <description>Change in the Percentage of Nights With Awakenings Due to Asthma from baseline (calculated as a mean using all available data for the 10 last days of run-in period) to week 6 (calculated as a mean using all available data after randomization, with run-in values as covariate). No imputation of missing data was performed. The participants answered &quot;Yes&quot; or &quot;No&quot; whether she/he woke up during the night due to asthma.</description>
        <time_frame>Baseline and 6 weeks</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Symbicort pMDI</title>
            <description>Symbicort®pMDI® 40/2.25 μg 2 Actuations Twice Daily</description>
          </group>
          <group group_id="O2">
            <title>Symbicort Turbuhaler</title>
            <description>Symbicort Turbuhaler® 80/4.5 μg 1 Inhalation Twice Daily</description>
          </group>
          <group group_id="O3">
            <title>Pulmicort Turbuhaler</title>
            <description>Pulmicort®Turbuhaler® 100 μg 1 Inhalation Twice Daily</description>
          </group>
        </group_list>
        <measure>
          <title>Percentage of Nights With Awakenings Due to Asthma</title>
          <description>Change in the Percentage of Nights With Awakenings Due to Asthma from baseline (calculated as a mean using all available data for the 10 last days of run-in period) to week 6 (calculated as a mean using all available data after randomization, with run-in values as covariate). No imputation of missing data was performed. The participants answered &quot;Yes&quot; or &quot;No&quot; whether she/he woke up during the night due to asthma.</description>
          <units>Percentage of night</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="253"/>
                <count group_id="O2" value="245"/>
                <count group_id="O3" value="243"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-14.0" spread="24.1"/>
                    <measurement group_id="O2" value="-14.0" spread="26.4"/>
                    <measurement group_id="O3" value="-8.3" spread="25.5"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Use of Rescue Medication, Night</title>
        <description>Change in the Use of Rescue Medication (Night) from baseline (calculated as a mean using all available data for the 10 last days of run-in period) to week 6 (calculated as a mean using all available data after randomization, with run-in values as covariate). No imputation of missing data was performed</description>
        <time_frame>Baseline to 6 weeks</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Symbicort pMDI</title>
            <description>Symbicort®pMDI® 40/2.25 μg 2 Actuations Twice Daily</description>
          </group>
          <group group_id="O2">
            <title>Symbicort Turbuhaler</title>
            <description>Symbicort Turbuhaler® 80/4.5 μg 1 Inhalation Twice Daily</description>
          </group>
          <group group_id="O3">
            <title>Pulmicort Turbuhaler</title>
            <description>Pulmicort®Turbuhaler® 100 μg 1 Inhalation Twice Daily</description>
          </group>
        </group_list>
        <measure>
          <title>Use of Rescue Medication, Night</title>
          <description>Change in the Use of Rescue Medication (Night) from baseline (calculated as a mean using all available data for the 10 last days of run-in period) to week 6 (calculated as a mean using all available data after randomization, with run-in values as covariate). No imputation of missing data was performed</description>
          <units>Inhalations</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="253"/>
                <count group_id="O2" value="245"/>
                <count group_id="O3" value="243"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-0.41" spread="0.64"/>
                    <measurement group_id="O2" value="-0.39" spread="0.76"/>
                    <measurement group_id="O3" value="-0.19" spread="0.67"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Use of Rescue Medication, Day</title>
        <description>Change in the Use of Rescue Medication (Day) from baseline (calculated as a mean using all available data for the 10 last days of run-in period) to week 6 (calculated as a mean using all available data after randomization, with run-in values as covariate). No imputation of missing data was performed</description>
        <time_frame>Baseline to 6 weeks</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Symbicort pMDI</title>
            <description>Symbicort®pMDI® 40/2.25 μg 2 Actuations Twice Daily</description>
          </group>
          <group group_id="O2">
            <title>Symbicort Turbuhaler</title>
            <description>Symbicort Turbuhaler® 80/4.5 μg 1 Inhalation Twice Daily</description>
          </group>
          <group group_id="O3">
            <title>Pulmicort Turbuhaler</title>
            <description>Pulmicort®Turbuhaler® 100 μg 1 Inhalation Twice Daily</description>
          </group>
        </group_list>
        <measure>
          <title>Use of Rescue Medication, Day</title>
          <description>Change in the Use of Rescue Medication (Day) from baseline (calculated as a mean using all available data for the 10 last days of run-in period) to week 6 (calculated as a mean using all available data after randomization, with run-in values as covariate). No imputation of missing data was performed</description>
          <units>Inhalations</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="253"/>
                <count group_id="O2" value="245"/>
                <count group_id="O3" value="243"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-0.21" spread="0.39"/>
                    <measurement group_id="O2" value="-0.20" spread="0.47"/>
                    <measurement group_id="O3" value="-0.13" spread="0.56"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Use of Rescue Medication, Total</title>
        <description>Change in the Use of Rescue Medication (Total) from baseline (calculated as a mean using all available data for the 10 last days of run-in period) to week 6 (calculated as a mean using all available data after randomization, with run-in values as covariate). No imputation of missing data was performed</description>
        <time_frame>Baseline to 6 weeks</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Symbicort pMDI</title>
            <description>Symbicort®pMDI® 40/2.25 μg 2 Actuations Twice Daily</description>
          </group>
          <group group_id="O2">
            <title>Symbicort Turbuhaler</title>
            <description>Symbicort Turbuhaler® 80/4.5 μg 1 Inhalation Twice Daily</description>
          </group>
          <group group_id="O3">
            <title>Pulmicort Turbuhaler</title>
            <description>Pulmicort®Turbuhaler® 100 μg 1 Inhalation Twice Daily</description>
          </group>
        </group_list>
        <measure>
          <title>Use of Rescue Medication, Total</title>
          <description>Change in the Use of Rescue Medication (Total) from baseline (calculated as a mean using all available data for the 10 last days of run-in period) to week 6 (calculated as a mean using all available data after randomization, with run-in values as covariate). No imputation of missing data was performed</description>
          <units>Inhalations</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="253"/>
                <count group_id="O2" value="245"/>
                <count group_id="O3" value="243"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-0.62" spread="0.89"/>
                    <measurement group_id="O2" value="-0.58" spread="1.09"/>
                    <measurement group_id="O3" value="-0.32" spread="1.12"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Percentage of Symptom-free Days</title>
        <description>Change in the Percentage of Symptom-free Days from baseline (calculated as a mean using all available data for the 10 last days of run-in period) to week 6 (calculated as a mean using all available data after randomization, with run-in values as covariate). No imputation of missing data was performed. Symptom-free Day: no symptoms (asthma symptom score=0) night and day, and no awakenings due to asthma.</description>
        <time_frame>Baseline to 6 weeks</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Symbicort pMDI</title>
            <description>Symbicort®pMDI® 40/2.25 μg 2 Actuations Twice Daily</description>
          </group>
          <group group_id="O2">
            <title>Symbicort Turbuhaler</title>
            <description>Symbicort Turbuhaler® 80/4.5 μg 1 Inhalation Twice Daily</description>
          </group>
          <group group_id="O3">
            <title>Pulmicort Turbuhaler</title>
            <description>Pulmicort®Turbuhaler® 100 μg 1 Inhalation Twice Daily</description>
          </group>
        </group_list>
        <measure>
          <title>Percentage of Symptom-free Days</title>
          <description>Change in the Percentage of Symptom-free Days from baseline (calculated as a mean using all available data for the 10 last days of run-in period) to week 6 (calculated as a mean using all available data after randomization, with run-in values as covariate). No imputation of missing data was performed. Symptom-free Day: no symptoms (asthma symptom score=0) night and day, and no awakenings due to asthma.</description>
          <units>Percentage of days</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="253"/>
                <count group_id="O2" value="245"/>
                <count group_id="O3" value="243"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="12.5" spread="23.7"/>
                    <measurement group_id="O2" value="15.3" spread="24.5"/>
                    <measurement group_id="O3" value="9.1" spread="21.2"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Percentage of Asthma Control Days</title>
        <description>Change in the Percentage of Symptom Control Days from baseline (calculated as a mean using all available data for the 10 last days of run-in period) to week 6 (calculated as a mean using all available data after randomization, with run-in values as covariate). No imputation of missing data was performed. Asthma Control Day: no symptoms (asthma symptom score=0) night and day, no awakenings due to asthma, no rescue medication.</description>
        <time_frame>Baseline to 6 weeks</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Symbicort pMDI</title>
            <description>Symbicort®pMDI® 40/2.25 μg 2 Actuations Twice Daily</description>
          </group>
          <group group_id="O2">
            <title>Symbicort Turbuhaler</title>
            <description>Symbicort Turbuhaler® 80/4.5 μg 1 Inhalation Twice Daily</description>
          </group>
          <group group_id="O3">
            <title>Pulmicort Turbuhaler</title>
            <description>Pulmicort®Turbuhaler® 100 μg 1 Inhalation Twice Daily</description>
          </group>
        </group_list>
        <measure>
          <title>Percentage of Asthma Control Days</title>
          <description>Change in the Percentage of Symptom Control Days from baseline (calculated as a mean using all available data for the 10 last days of run-in period) to week 6 (calculated as a mean using all available data after randomization, with run-in values as covariate). No imputation of missing data was performed. Asthma Control Day: no symptoms (asthma symptom score=0) night and day, no awakenings due to asthma, no rescue medication.</description>
          <units>Percentage of days</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="253"/>
                <count group_id="O2" value="245"/>
                <count group_id="O3" value="243"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="12.7" spread="23.6"/>
                    <measurement group_id="O2" value="15.1" spread="24.4"/>
                    <measurement group_id="O3" value="9.1" spread="21.2"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Percentage of Rescue Free Days</title>
        <description>Change in the Percentage of Rescue Free Days from baseline (calculated as a mean using all available data for the 10 last days of run-in period) to week 6 (calculated as a mean using all available data after randomization, with run-in values as covariate). No imputation of missing data was performed. Rescue-free Day defined as day and night with no use of rescue medication.</description>
        <time_frame>Baseline to 6 weeks</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Symbicort pMDI</title>
            <description>Symbicort®pMDI® 40/2.25 μg 2 Actuations Twice Daily</description>
          </group>
          <group group_id="O2">
            <title>Symbicort Turbuhaler</title>
            <description>Symbicort Turbuhaler® 80/4.5 μg 1 Inhalation Twice Daily</description>
          </group>
          <group group_id="O3">
            <title>Pulmicort Turbuhaler</title>
            <description>Pulmicort®Turbuhaler® 100 μg 1 Inhalation Twice Daily</description>
          </group>
        </group_list>
        <measure>
          <title>Percentage of Rescue Free Days</title>
          <description>Change in the Percentage of Rescue Free Days from baseline (calculated as a mean using all available data for the 10 last days of run-in period) to week 6 (calculated as a mean using all available data after randomization, with run-in values as covariate). No imputation of missing data was performed. Rescue-free Day defined as day and night with no use of rescue medication.</description>
          <units>Percentage of days</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="253"/>
                <count group_id="O2" value="245"/>
                <count group_id="O3" value="243"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="24.0" spread="30.9"/>
                    <measurement group_id="O2" value="26.2" spread="30.7"/>
                    <measurement group_id="O3" value="17.2" spread="28.4"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Forced Expiratory Volume in 1 Second (FEV1)</title>
        <description>Change in the FEV1from baseline to week 6 (calculated as a mean using all available data after randomization)</description>
        <time_frame>Baseline to 6 weeks</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Symbicort pMDI</title>
            <description>Symbicort®pMDI® 40/2.25 μg 2 Actuations Twice Daily</description>
          </group>
          <group group_id="O2">
            <title>Symbicort Turbuhaler</title>
            <description>Symbicort Turbuhaler® 80/4.5 μg 1 Inhalation Twice Daily</description>
          </group>
          <group group_id="O3">
            <title>Pulmicort Turbuhaler</title>
            <description>Pulmicort®Turbuhaler® 100 μg 1 Inhalation Twice Daily</description>
          </group>
        </group_list>
        <measure>
          <title>Forced Expiratory Volume in 1 Second (FEV1)</title>
          <description>Change in the FEV1from baseline to week 6 (calculated as a mean using all available data after randomization)</description>
          <units>Liters</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="253"/>
                <count group_id="O2" value="243"/>
                <count group_id="O3" value="242"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.095" spread="0.328"/>
                    <measurement group_id="O2" value="0.147" spread="0.364"/>
                    <measurement group_id="O3" value="0.112" spread="0.326"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
    </outcome_list>

    <reported_events>
      <group_list>
        <group group_id="E1">
          <title>Symbicort pMDI</title>
          <description>Symbicort pMDI</description>
        </group>
        <group group_id="E2">
          <title>Symbicort Turbuhaler</title>
          <description>Symbicort Turbuhaler</description>
        </group>
        <group group_id="E3">
          <title>Pulmicort Turbuhaler</title>
          <description>Pulmicort Turbuhaler</description>
        </group>
      </group_list>
      <serious_events>
        <default_vocab>MedDRA 10.1</default_vocab>
        <default_assessment>Systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, serious adverse events</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="253"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="246"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="243"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Respiratory, thoracic and mediastinal disorders</title>
            <event_list>
              <event>
                <sub_title>Asthma</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="253"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="246"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="243"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </serious_events>
      <other_events>
        <frequency_threshold>5</frequency_threshold>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, other adverse events</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="253"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="246"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="243"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </other_events>
    </reported_events>

    <certain_agreements>
      <pi_employee>Principal Investigators are NOT employed by the organization sponsoring the study.</pi_employee>
      <restrictive_agreement>There is NOT an agreement between Principal Investigators and the Sponsor (or its agents) that restricts the PI's rights to discuss or publish trial results after the trial is completed. </restrictive_agreement>
    </certain_agreements>
    <point_of_contact>
      <name_or_title>Gerard Lynch</name_or_title>
      <organization>AstraZeneca</organization>
      <email>aztrial_results_posting@astrazeneca.com</email>
    </point_of_contact>
  </clinical_results>
</clinical_study>

